| Bioactivity | Anumigilimab (CSL-324) is an humanized IgG2a mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation[1][2]. |
| Target | granulocyte colony-stimulating factor (G-CSF) receptor |
| Name | Anumigilimab |
| CAS | 2416593-08-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Markota Čagalj A, et al. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci. 2022 Mar 29;23(7):3753. [2]. Rosales Santillan M, et al. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2020 Jun;20(6):621-633. |